anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention discloses one kind of recombinant plasmid containing grass carp interferon gene with the nucleotide sequence as shown in SEQ ID No. 1. The present invention also discloses engineering bacterium INVSC1-pYES2-IFN as one kind of Saccharomyces cerevisiae in the preservation number of CGMCC1847. The engineering bacterium is used for aquatic animals to resist viruses. The present invention also discloses the application of protein coded by the recombinant plasmid containing grass carp interferon gene with the nucleotide sequence as shown in SEQ ID No. 1 for aquatic animals to resist viruses.
Native Hawaiians (NH) have higher rates of chronic diseases, such as cardiovascular disease (CVD), diabetes, and cancer. Hypertension (HTN), an important modifiable risk factor for CVD, is 70% higher in Native Hawaiians (NH) than in Whites. In fact, NH are 3-4 times more likely to develop CVD conditions, such as stroke and coronary heart disease, and at a younger age. In addition to prescribed medication, improvements in HTN can be achieved through increased physical activity (PA) and self-management education (e.g. stress management, reduces sodium intake, weight-loss, and smoking cessation). Yet, many commonly prescribed PA, such as jogging and use of treadmills, are difficult for NH to initiate and maintain because of socioeconomic barriers and lack of alignment with NH preferred modes of living and cultural values (i.e. familial interdependence, group-based PA, cultural PA).

This research study uses hula, the traditional dance form of NH and hallmark of NH culture, as the PA basis for a culturally relevant and sustainable CVD prevention program targeting HTN management. Hula training is popular, not only Hawai'i, but across the U.S. through the 784 hālau hula (hula schools) found in most States. Using a community-based participatory research (CBPR) framework, a hula-based CVD health intervention was strongly endorsed by Kumu hula (hula experts and guardians of hula traditions), NH individuals, and communities. Further, hula was determined to yield metabolic equivalent of energy expenditure as a moderate and vigorous intensity PA. Data from a pilot CBPR randomized control trial (RCT) study found that 60 minutes of hula training twice a week for 12 weeks reduced systolic blood pressure (BP) by 7.5 mmHg (SD=16.5) more than the control group, but the long-term effects were mixed and the study did not assess CVD risk.

Interestingly, the pilot intervention also improved social functioning, reduced physical pain, and perceived racial discrimination, suggesting a possible psychosocial and socio-cultural mechanism by which the intervention affects BP. In this study a CBPR guided RCT of 250 NH with physician-diagnosed HTN in Hawai'i and Washington State is offered. The effects will be compared of a 6-month intervention that combines hula training and brief culturally-tailored HTN self-management education delivered by peer educators and Kumu hula to a wait-list control group in reducing systolic BP and CVD risk scores. It will also be determined the mediating effects of health behaviors (e.g., smoking), self-regulation, and psychosocial (e.g., social support), and socio-cultural factors (e.g., perceived racism) on blood pressure reduction. The goal is to build on the existing widespread infrastructure of hālau hula and NH organizations to deliver a sustainable, culturally-preferred CVD prevention program.
After applying the dry needling technique to the upper trapezius muscle, the patient remains supine position. The analytical passive stretch of the upper trapezius will be performed only once, bringing the muscle to the limit of elastic tension perceived by the subject. The passive stretching technique will be held for 30 seconds.
A total of 1050 recipients aged 18-59 years were enrolled in this study. Blood samples were collected before and 30 days after vaccination. Hemagglutination inhibition (HI) antibody to influenza virus was detected in the serum of all recipients to evaluate the inter-batch consistency of the vaccine.
Endoscopic sinus surgery is commonly used to manage chronic inflammatory frontal sinus disease that is not adequately controlled with medical therapy alone. In recalcitrant cases, a more extensive procedure called the modified endoscopic Lothrop procedure or frontal drill-out (FDO) procedure is often performed. The frontal drill-out procedure is performed endoscopically and its goal is to create one large common cavity between the left and right frontal sinuses and nasal cavities to allow adequate drainage and communication for subsequent drug delivery through sinonasal irrigations if indicated. Failure of this procedure is most commonly the results of re-stenosis of the outflow tract due to scarring, adhesions, or progressive disease such as polyposis. One meta analysis assessing the long-term complications of frontal drillouts reported an overall failure rate to be 13.9%, defined as those individuals needing further surgery. Another clinical trial reported a failure rate for a 200-person study to be 30%.

Placing a steroid-eluding biodegradable stent into the sinonasal cavities after surgery is thought to reduce the occurrence of re-stenosis, both by physically stenting the opening and by treating resultant inflammation with corticosteroid. Propel stents are made of synthetic dissolvable polymer that contains a corticosteroid (mometasone furoate) and has been FDA-approved to stent and reduce inflammation over 30 days. Similarly, Nasopore is an FDA-approved fragmentable nasal dressing that is used as a stent. Kenalog soaking the Nasopore is thought to act as the functional equivalent of the mometasone furoate found in the Propel stent, but this use is investigational. The effect of stenting and its consequences on the outcomes of FDO specifically has also not been well studied.Recent randomized-controlled trial of Propel stent placement after frontal sinusotomy (a less extensive form of frontal sinus surgery compared to FDO procedure) showed improvement in outcomes compared to no stent placement and no major complications.There are no known randomized-controlled trials to date of propel stent placement or Nasopore-soaked Kenalog placement after FDO procedure. We wish, therefore, to perform a randomized trial to compare the efficacy and outcomes of Nasopore-soaked kenalog versus propel stenting.
The present invention relates to application of gossypol and its optical isomers to preparation of an anti- Coronavirus  drug. Specifically disclosed is application of pharmaceutically acceptable salts, solvates, isotopes, stereoisomers, stereoisomer mixtures, and tautomers of the gossypol and its optical isomers to preparation of a drug for preventing and/or treating a disease caused by a  Coronavirus.  The  Coronavirus  is MERS-CoV, SARS-CoV, or SARS-CoV-2. It is found in the present invention for the first time that the gossypol and its optical isomers can inhibit the activity of  Coronavirus  3CL proteases to achieve an anti- Coronavirus  effect. The half maximal inhibitory concentrations of gossypol and (−)-gossypol to SARS-CoV proteases and SARS-CoV-2 3CL proteases are all lower than 10 μM. The anti- Coronavirus  3CL protease effect is good. Therefore, the gossypol and its optical isomers have the potential for use in the preparation of a drug for preventing and/or treating novel  Coronavirus  infections.
Although multiple approaches have been suggested, treating mild-to-severe fibrosis in the context of metabolic dysfunction associated with liver disease (MASLD) remains a challenging area in drug discovery. Pathogenesis of liver fibrosis is multifactorial, and pathogenic mechanisms are deeply intertwined; thus, it is well accepted that future treatment requires the development of multitarget modulators. Harnessing the 3,4,5-trisubstituted isoxazole scaffold, previously described as a key moiety in Farnesoid X receptor (FXR) agonism, herein we report the discovery of a novel class of hybrid molecules endowed with dual activity toward FXR and the leukemia inhibitory factor receptor (LIFR). Up to 27 new derivatives were designed and synthesized. The pharmacological characterization of this series resulted in the identification of 3a as a potent FXR agonist and LIFR antagonist with excellent ADME properties. In vitro and in vivo characterization identified compound 3a as the first-in-class hybrid LIFR inhibitor and FXR agonist that protects against the development of acute liver fibrosis and inflammation.
FIELD: medicine.SUBSTANCE: invention relates to a polymer conjugate, a polymer micelle formed by a polymer conjugate, a therapeutic composition for treating cancer, and a method for treating a disease or condition which is cancer. In the method, the polymer conjugate contains a backbone, which is an anionic polymer, and hydrophobic moieties are covalently attached to the backbone of the polymer. Said polymer conjugate has following formula (I):, where M is independently selected from the group consisting of hydrophobic moiety and cation; the hydrophobic moiety is independently selected from:or. Said hydrophobic moiety is 20–50 mol% of total M amount; the cation is independently selected from hydrogen, ammonia or alkali metal; X is O. Above cancer treatment therapeutic composition contains a carrier consisting of the above polymer conjugate and a hydrophobic compound functionally associated with the carrier. In the method, a hydrophobic drug is an anticancer drug. This method for treating cancer is that an effective amount of the above therapeutic composition is administered to a subject.EFFECT: invention makes it possible to obtain stable polymer micelles, increase the therapeutic effect and improve the condition of a patient.6 cl, 6 dwg, 2 tbl, 8 ex
The slow released compound anticancer injection containing blood vessel inhibitor and its synergist consists of slow released microsphere and solvent. The slow released microsphere includes effective anticancer component and slow releasing supplementary material, and the solvent is common solvent or special solvent containing suspending agent. The effective anticancer component is blood vessel inhibitor and/or blood vessel inhibitor synergist selected from antitumor antibiotic and antimetabolite. The slow releasing supplementary material is selected from difatty acid-sebacic acid copolymer, poly(erucic acid dipolymer-sebacic acid), poly(fumaric acid-sebacic acid), etc or their composition. The suspending agent is carboxymethyl cellulose, etc. and has viscosity of 80-3000 cp at 20-30 deg.c. The slow released microsphere may be also prepared into slow released implanting agent for use alone or together with chemotherapeutic and/or radiotherapeutic medicine..
A wearable cardiotoxicity monitoring system for monitoring cardiotoxicity biosignal markers in oncology patients is provided. The system includes a wearable cardiotoxicity monitoring device configured for long-term, continuous wear by a patient, including externally applied biosignal sensors configured to sense biosignal(s) from the patient and a controller. The externally applied biosignal sensors include ECG electrodes and at least one non-ECG physiological sensor. The controller is configured to transmit biosignal-based data based on the sensed biosignal(s) to a remote server. The system further includes the remote server, including a memory and a processor. The processor is configured to receive the biosignal-based data, analyze the biosignal-based data to identify cardiotoxicity biosignal marker(s) associated with heart failure caused by chemotherapy and/or radiation therapy cardiotoxicity, determine a current status of cardiotoxicity in the patient based on the cardiotoxicity biosignal marker(s), and generate an output based on the current status of cardiotoxicity.
The design of the Montessori Method for Dementia program covered five aspects, namely cognitive stimulation, life skills, motor movements and fitness, sensory stimulation, and socialization. Each 1-hour session included two to three activities tailored to the local cultural context.
Application in the Control Group: After the theoretical lesson, the control group was taken to the Nursing Fundamentals Skills Laboratory. The laboratory consists of 3 practice rooms, 1 control room and 1 analysis room. A video prepared by the researcher on the Simple Nasogastric Tube Application Model in line with the steps of "Checklist for Teaching Nasogastric Tube Application Skills" was watched and preliminary information was given. The questions were answered by allowing the students to ask questions.
The neurological deficits following traumatic spinal cord injury are associated with severe patient disability and economic consequences. Currently, an increasing number of studies are focusing on the importance of ferroptosis during acute organ injuries. However, the spatial and temporal distribution patterns of ferroptosis during SCI and the details of its role are largely unknown. In this study, in vivo experiments revealed that microglia are in close proximity to macrophages, the major cell type that undergoes ferroptosis following SCI. Furthermore, we found that ferroptotic macrophages aggravate SCI by inducing the proinflammatory properties of microglia. In vitro studies further revealed ferroptotic macrophages increased the expression of IL-1β, IL-6, and IL-23 in microglia. Mechanistically, due to the activation of the NF-κB signaling pathway, the expression of IL-1β and IL-6 was increased. In addition, we established that increased levels of oxidative phosphorylation cause mitochondrial reactive oxygen species generation and unfolded protein response activation and trigger an inflammatory response marked by an increase in IL-23 production. Our findings identified that targeting ferroptosis and IL-23 could be an effective strategy for promoting neurological recovery after SCI.
Routine treatment and care of patients in the CG was continued. The onset of bowel sounds and flatus requires the initiation of oral fluid and nutrient intake. Patients in the CG were evaluated at T0, T1, T2, and T3, and data were recorded on a data collection form.
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to otorhinolaryngology, and can be used for treating patients with olfactory dysfunction in atrophic rhinitis. Method includes preliminary diagnosing of olfactory function disorder with calculation of total score by "Sniffin' Sticks Test". If total test score is 1–15 points, functional anosmia – residual ability to olfaction is diagnosed, at 16–30 points, hyposmia – smell reduction – is diagnosed. Treatment of olfactory dysfunction involves: irrigation therapy – washing the nasal cavity with 0.9 % NaCl physiological solution in amount of 5–10 ml for 5 minutes daily 2 times day for 3 weeks; olfactory training using rose oil, eucalyptus, lemon and cloves, which are brought to vestibule for 10 seconds for each, with interval of 10 seconds for 84 to 252 days. Simultaneously, a medicamentous therapy with Neuromidine is used. In functional anosmia with total test score of 1–15 points by intramuscular introduction in amount of 5 to 15 mg/ml 1-2 times day for 10 days, followed by treatment with Neuromidine 1 tablet 10 to 20 mg 3 times day for 28 days. If hyposmia with total test score of 16–30 points by intramuscular introduction in amount of 5 mg/ml 2 times day for 10 days, followed by treatment with Neuromidine 1 tablet 10 to 20 mg 2 times day for 28 days.EFFECT: method enables higher clinical effectiveness in olfactory dysfunction by acting on peripheral olfactory tract, and stimulation of olfactory epithelial cell regeneration by olfactory trainings and using Neuromedin preparation, which has a direct stimulating effect on the impulse as per the nerve fiber.1 cl, 2 dwg, 1 ex
Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-DOTA-NI-FAPI04. Tracer doses of 68Ga-DOTA-NI-FAPI04 will be used to detect tumors by PET/CT.
Disclosed herein is a programmable medication dispenser. Further, the programmable medication dispenser may include a housing, a base wall, at least one actuator, at least one power source, a processing device, and a storage device. Further, the housing may include a body and at least one bottomless tray configured to be movably disposed within the at least one interior space. Further, the at least one bottomless tray may include a plurality of compartments. Further, the base wall disposed on one side of the at least one bottomless tray. Further, the at least one actuator may be coupled to the at least one bottomless tray. Further, the at least one power source configured to provide power to the at least one actuator. Further, the processing device may be communicatively coupled to the at least one actuator. Further, the storage device may be communicatively coupled to the processing device.
In the mammalian isocortex, CD44, a cell surface receptor for extracellular matrix molecules, is present in pial-based and fibrous astrocytes of white matter but not in protoplasmic astrocytes. In the hominid isocortex, CD44+ astrocytes comprise the subpial "interlaminar" astrocytes, sending long processes into the cortex. The hippocampus also contains similar astrocytes. We have examined all levels of the human central nervous system and found CD44+ astrocytes in every region. Astrocytes in white matter and astrocytes that interact with large blood vessels but not with capillaries in gray matter are CD44+, the latter extending long processes into the parenchyma. Motor neurons in the brainstem and spinal cord, such as oculomotor, facial, hypoglossal, and in the anterior horn of the spinal cord, are surrounded by CD44+ processes, contrasting with neurons in the cortex, basal ganglia, and thalamus. We found CD44+ processes that intercalate between ependymal cells to reach the ventricle. We also found CD44+ astrocytes in the molecular layer of the cerebellar cortex. Protoplasmic astrocytes, which do not normally contain CD44, acquire it in pathologies like hypoxia and seizures. The pervasive and inducible expression of CD44 in astrocytes is a novel finding that lays the foundations for functional studies into the significance of CD44 in health and disease.
PURPOSE: A composition for diagnosing gestosis containing a marker protein is provided to quickly and simply diagnose a novel marker protein at once. CONSTITUTION: A composition for diagnosing gestosis contains Insulin like growth factor binding protein, acid labile subunit(IGFBP, ALS), alpha2-HS-glycoprotein(AHSG. Fetuin), retinol binding protein 4(RBP4), or alpha-1-microglobin/bikunin(AMBP) protein as an active ingredient. The IGFBP subunit has an amino acid sequence of sequence number 1. The AHSG has an amino acid sequence of sequence number 2. The RBP4 has an amino acid sequence of sequence number 3. The AMBP has an amino acid sequence of sequence number 4. A method for selecting a gestosis-specific protein comprises: a step of fragmenting sample from healthy person group and patient group; a step of performing liquid chromatography/mass spectrography(LC-MS/MS) using fragment peptide to identify total protein; and a step of comparing protein peak.
Electroencephalography (EEG) is widely used to monitor epileptic seizures, and standard clinical practice consists of monitoring patients in dedicated epilepsy monitoring units via video surveillance and cumbersome EEG caps. Such a setting is not compatible with long-term tracking under typical living conditions, thereby motivating the development of unobtrusive wearable solutions. However, wearable EEG devices present the challenges of fewer channels, restricted computational capabilities, and lower signal-to-noise ratio. Moreover, artifacts presenting morphological similarities to seizures act as major noise sources and can be misinterpreted as seizures. This paper presents a combined seizure and artifacts detection framework targeting wearable EEG devices based on Gradient Boosted Trees. The seizure detector achieves nearly zero false alarms with average sensitivity values of [Formula: see text] for 182 seizures from the CHB-MIT dataset and [Formula: see text] for 25 seizures from the private dataset with no preliminary artifact detection or removal. The artifact detector achieves a state-of-the-art accuracy of [Formula: see text] (on the TUH-EEG Artifact Corpus dataset). Integrating artifact and seizure detection significantly reduces false alarms-up to [Formula: see text] compared to standalone seizure detection. Optimized for a Parallel Ultra-Low Power platform, these algorithms enable extended monitoring with a battery lifespan reaching 300 h. These findings highlight the benefits of integrating artifact detection in wearable epilepsy monitoring devices to limit the number of false positives.
Described is a method of determining whether repair or replacement of an electron gun of a radiotherapy device should be scheduled. The radiotherapy device comprises a linear accelerator and is configured to provide therapeutic radiation to a patient. The radiotherapy device comprises a vacuum tube comprising the electron gun, a waveguide configured to accelerate electrons emitted by the electron gun toward a target to produce said radiation. The radiotherapy device comprises also comprises a current sensor, the current sensor being configured to provide signals indicative of current supplied to the electron gun. The method comprises receiving a current value, processing the current value, and based on the processing of the current value, determining whether repair or replacement of the electron gun should be scheduled. Processing the current value comprises determining whether the current value meets at least one threshold criterion, and determining whether the current value has changed by at least a threshold amount in a particular time period.
ZTALMY is administered by mouth three times daily and must be taken with food [see Clinical Pharmacology (12.3)].

The recommended titration schedule and maintenance dosage are based on body weight for patients weighing 28 kg or less. Dosage recommendations for patients with severe hepatic impairment and weighing 28 kg or less are included in Table 3, and dosage recommendations for patients with severe hepatic impairment (Child-Pugh class C) weighing more than 28 kg are included in Table 4. Dosage should be increased based on tolerability no more frequently than every 7 days. Titration increments should not exceed those shown in Table 3 and Table 4.

No dosage adjustment is necessary in patients with mild (Child-Pugh class A) or moderate (Child-Pugh class B) hepatic impairment.